₇S Vermeire

Summary for 2004 [at-glance overview of S Vermeire work for the selected year as suggested by data mining algorithms]

This is an Authoratory overview of author S Vermeire. According to available data, in 2004 S Vermeire published at least 7 articles. This work was completed in collaboration with several authors including Rutgeerts, P and Van Gossum, A. Many other authors have collaborated with S Vermeire as well. There is no information about the funding or the grants awarded to support this work.

S Vermeire is a key opinion leader in the specific area of Gastrointestinal Agents. This author's rank is 3 when compared to all other authors using the same keyword. Analysis of the article abstracts and the titles suggests that S Vermeire professional interests are focused around "inflammatory bowel disease", "crohn disease patients" and "tumour necrosis factor-alpha". These might also be referred to as "crohn disease", "inflammatory bowel" or "response infliximab". Statistical analysis shows that S Vermeire's writing is likely to contains terms "disease", "crohn", "infliximab", "patients", "response" and "associated".

The majority of S Vermeire articles are affiliated with Department of Gastroenterology, at the University Hospital Gasthuisberg, Leuven, Belgium. Luckily, one email address is on file.

EN FR ES RU

Inaccurate information, needs improvement

make correction leave comment ask question

Images [images we found on the Internet for S Vermeire]

Do you know S Vermeire who matches the profile above? Click the photo and let us know!

Alternative names (1) [other authors with names similar to S Vermeire]

₁₁₀Vermeire, Séverine

Year 2004 Charts [S Vermeire frequent coauthors and the most common unique vocabulary terms for the selected year]

Historical Performance Charts [graphical overview of S Vermeire publication and funding history for the range of years]

Emails (1) [email addresses extracted from S Vermeire affiliations]

hidden to prevent spam, click here to reveal

S Vermeire Coauthors (32) [all coauthors with the number of joint publications]

7

3

3

2

2

2

2

2

2

2

2

2

2

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

Other [context-specific ads]

Affiliations (4) [condensed summary of the S Vermeire affiliations, the leading number and the color conveys importance]

₄Department of Gastroenterology, at the University Hospital Gasthuisberg, Leuven, Belgium.
₁Rheumatology Department, CHU Liège, Belgium.
₁Department of Gastroenterology, Erasme University Hospital, Brussels, Belgium.
₁Department of Gastroenterology, CHU of Liège, Liège, Belgium.

Key Opinion Leader In [S Vermeire is considered a key opinion leader in any keyword where the rank of 5 is achieved, the leading number before the keyword shows the author's rank as compared to all other authors]

₃Gastrointestinal Agents | ₁₃Crohn Disease | ₅₈Colitis, Ulcerative | ₁₂₄Antibodies, Monoclonal | ₆₆₆Polymorphism, Genetic

Keywords (32) [keywords assigned to S Vermeire articles by PubMed, the leading number and the color conveys importance]

₇Humans | ₇Female | ₇Male | ₆Crohn Disease | ₅Gastrointestinal Agents | ₅Adult | ₄Adolescent | ₄Middle Aged | ₄Antibodies, Monoclonal | ₃Colitis, Ulcerative | ₃Polymorphism, Genetic | ₃Treatment Outcome | ₃Aged | ₂Genotype | ₂Genetic Predisposition to Disease | ₁Cytokines | ₁C-Reactive Protein | ₁Follow-Up Studies | ₁Immunosuppressive Agents | ₁Biological Products | ₁Nod2 Signaling Adaptor Protein | ₁Colectomy | ₁Membrane Glycoproteins | ₁Chromosomes, Human, Pair 14 | ₁Carrier Proteins | ₁Epistasis, Genetic | ₁Retrospective Studies | ₁Cohort Studies | ₁Linkage (Genetics) | ₁Receptors, Cell Surface | ₁Bone Density | ₁Toll-Like Receptors

S Vermeire Unique Vocabulary (96) [single words, word pairs and phrases obtained by analysis of abstracts and titles, the leading number and the color conveys importance; S Vermeire might be a good expert witness on these terms]

₃₇disease | ₂₆crohn | ₂₄infliximab | ₂₁patients | ₁₅response | ₁₄associated | ₁₃polymorphism | ₁₃ibd | ₁₂inflammatory | ₁₂bone | ₁₁bowel | ₁₀colitis | ₁₀ulcerative | ₉association | ₉population | ₈treatment | ₈biological | ₇polymorphisms | ₇results | ₇asp299gly | ₇tlr4 | ₆conclusion | ₆linkage | ₆flemish | ₅compared | ₅factor-alpha | ₅drugs | ₅susceptibility | ₅methods | ₅necrosis | ₄tumour | ₄observed
₂₆crohn disease | ₁₁inflammatory bowel | ₁₁response infliximab | ₁₀ulcerative colitis | ₈bowel disease | ₇asp299gly polymorphism | ₆confidence interval | ₅necrosis factor-alpha | ₅disease patients | ₅bone metabolism | ₄biological response | ₄tumour necrosis | ₄tlr4 asp299gly | ₄infliximab therapy | ₄genome wide | ₃bowel disorders | ₃population heterogeneity | ₃flemish ibd | ₃association response | ₃susceptibility regions | ₃wide scan | ₃disease association | ₃disease ulcerative | ₃c-reactive protein | ₃therapy crohn | ₂nominal evidence | ₂disease associated | ₂uc patients | ₂disease ibd | ₂evidence linkage | ₂formation markers | ₂according marker
₈inflammatory bowel disease | ₅crohn disease patients | ₄tumour necrosis factor-alpha | ₄tlr4 asp299gly polymorphism | ₃inflammatory bowel disorders | ₃therapy crohn disease | ₃disease association response | ₃disease ulcerative colitis | ₃biological response infliximab | ₃infliximab therapy crohn | ₃genome wide scan | ₃crohn disease ulcerative | ₃association response infliximab | ₂bowel disease ibd | ₂factor-alpha receptor polymorphisms | ₂necrosis factor-alpha receptor | ₂nucleotide polymorphisms negatively | ₂rapid improvement bone | ₂c-telopeptide type-i collagen | ₂receptor polymorphisms inflammatory | ₂management ulcerative colitis | ₂improvement bone metabolism | ₂polymorphisms inflammatory bowel | ₂infliximab treatment crohn | ₂polymorphisms negatively associated | ₂treatment crohn disease | ₂colitis crohn disease | ₂ulcerative colitis crohn | ₂crohn disease associated | ₂metabolism infliximab treatment | ₂nominal evidence linkage | ₂single nucleotide polymorphisms

Reader's Comments (0) [comments posted by readers of S Vermeire profile]